AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
YM Loo, PM McTamney, RH Arends, RA Gasser Jr… - Medrxiv, 2021 - medrxiv.org
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies
(mAbs) against the viral spike protein have potential to both prevent and treat COVID-19,
and reduce the risk of severe disease and death. Here, we describe AZD7442, a
combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that
simultaneously bind to distinct non-overlapping epitopes on the spike protein receptor …
and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies
(mAbs) against the viral spike protein have potential to both prevent and treat COVID-19,
and reduce the risk of severe disease and death. Here, we describe AZD7442, a
combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that
simultaneously bind to distinct non-overlapping epitopes on the spike protein receptor …
以上显示的是最相近的搜索结果。 查看全部搜索结果